Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
Plus Therapeutics (PSTV) has received a delinquency notification from Nasdaq on May 21, 2025, due to delayed filing of its Q1 2025 Quarterly Report (Form 10-Q). The company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the SEC.
While this notification has no immediate impact on PSTV's Nasdaq listing, the company must submit a compliance plan by July 21, 2025. If accepted, Nasdaq may grant an extension until November 17, 2025. Plus Therapeutics states it is working to file the report promptly and expects to resume normal filing schedules for the remainder of 2025.
Plus Therapeutics (PSTV) ha ricevuto una notifica di inadempienza da Nasdaq il 21 maggio 2025, a causa del ritardo nella presentazione del rapporto trimestrale del primo trimestre 2025 (Modulo 10-Q). La società non è conforme alla Regola di quotazione Nasdaq 5250(c)(1), che richiede la presentazione tempestiva dei rapporti finanziari periodici alla SEC.
Questa notifica non ha un impatto immediato sulla quotazione di PSTV su Nasdaq, ma l’azienda deve presentare un piano di conformità entro il 21 luglio 2025. Se approvato, Nasdaq potrebbe concedere una proroga fino al 17 novembre 2025. Plus Therapeutics dichiara di essere al lavoro per presentare il rapporto rapidamente e si aspetta di riprendere i normali programmi di presentazione per il resto del 2025.
Plus Therapeutics (PSTV) recibió una notificación de incumplimiento por parte de Nasdaq el 21 de mayo de 2025, debido al retraso en la presentación de su informe trimestral del primer trimestre de 2025 (Formulario 10-Q). La compañía no cumple con la Regla de Listado de Nasdaq 5250(c)(1), que exige la presentación oportuna de informes financieros periódicos ante la SEC.
Aunque esta notificación no afecta de inmediato la cotización de PSTV en Nasdaq, la empresa debe presentar un plan de cumplimiento antes del 21 de julio de 2025. Si es aceptado, Nasdaq podría otorgar una prórroga hasta el 17 de noviembre de 2025. Plus Therapeutics afirma que está trabajando para presentar el informe lo antes posible y espera reanudar los calendarios normales de presentación para el resto de 2025.
Plus Therapeutics (PSTV)는 2025년 5월 21일, 2025년 1분기 분기 보고서(Form 10-Q) 제출 지연으로 인해 나스닥으로부터 연체 통보를 받았습니다. 회사는 SEC에 정기 재무 보고서를 적시에 제출하도록 요구하는 나스닥 상장 규칙 5250(c)(1)을 준수하지 않고 있습니다.
이 통보는 PSTV의 나스닥 상장에 즉각적인 영향을 미치지는 않지만, 회사는 2025년 7월 21일까지 준수 계획을 제출해야 합니다. 승인될 경우 나스닥은 2025년 11월 17일까지 연장 허가를 할 수 있습니다. Plus Therapeutics는 신속한 보고서 제출을 위해 노력 중이며 2025년 나머지 기간 동안 정상적인 제출 일정을 재개할 것으로 예상하고 있습니다.
Plus Therapeutics (PSTV) a reçu une notification de manquement de la part du Nasdaq le 21 mai 2025, en raison du retard dans le dépôt de son rapport trimestriel du premier trimestre 2025 (formulaire 10-Q). La société n’est pas en conformité avec la règle de cotation Nasdaq 5250(c)(1), qui exige le dépôt en temps voulu des rapports financiers périodiques auprès de la SEC.
Cette notification n’a pas d’impact immédiat sur la cotation de PSTV au Nasdaq, mais l’entreprise doit soumettre un plan de conformité avant le 21 juillet 2025. Si ce plan est accepté, le Nasdaq pourrait accorder une prolongation jusqu’au 17 novembre 2025. Plus Therapeutics indique travailler à la soumission rapide du rapport et s’attend à reprendre les calendriers de dépôt normaux pour le reste de l’année 2025.
Plus Therapeutics (PSTV) hat am 21. Mai 2025 eine Mitteilung über eine Säumnis von der Nasdaq erhalten, da die Einreichung des Quartalsberichts für das erste Quartal 2025 (Formular 10-Q) verspätet erfolgte. Das Unternehmen entspricht nicht der Nasdaq-Listing-Regel 5250(c)(1), die eine fristgerechte Einreichung von periodischen Finanzberichten bei der SEC verlangt.
Diese Mitteilung hat keine unmittelbaren Auswirkungen auf die Nasdaq-Notierung von PSTV, jedoch muss das Unternehmen bis zum 21. Juli 2025 einen Compliance-Plan vorlegen. Wird dieser akzeptiert, kann die Nasdaq eine Fristverlängerung bis zum 17. November 2025 gewähren. Plus Therapeutics gibt an, daran zu arbeiten, den Bericht umgehend einzureichen und erwartet, den regulären Einreichungsplan für den Rest des Jahres 2025 wieder aufzunehmen.
- No immediate effect on Nasdaq listing
- Company has until July 21, 2025 to submit compliance plan
- Potential extension available until November 17, 2025 if plan is accepted
- Failed to file Q1 2025 Form 10-Q on time
- Non-compliance with Nasdaq listing requirements
- Risk of delisting if compliance is not regained within the given timeframe
HOUSTON, May 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Quarterly Report”). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). This notification has no immediate effect on the listing of the Company’s securities on Nasdaq.
Nasdaq has informed the Company that it must submit a plan to regain compliance with respect to the filing requirement by July 21, 2025. If the plan is accepted, Nasdaq can grant an exception of up to 180 calendar dates from the due date of the filing, or until November 17, 2025, to regain compliance.
The Company is working diligently to file the Quarterly Report as promptly as practical, and expects to return to a normal filing cadence for the remainder of 2025.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as assumptions about future events. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “expect,” “plan,” or “potential,” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements relating to the Company’s plans and expectations about the completion and filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2025, its submission of a plan to regain compliance with respect to the Nasdaq Listing Rule, and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to, uncertainties about the timing of the Company’s submission of a compliance plan, Nasdaq’s acceptance of any such plan, the duration of any extension that may be granted by Nasdaq, the potential inability to meet Nasdaq’s requirements, the Company’s preparation of the Quarterly Report on Form 10-Q for the period ended March 31, 2025 and the related financial statements, the possibility of additional delays in the filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2025, and the other risks and uncertainties described in the Company’s SEC reports and under the heading “Risk Factors” in its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release. Except as required by law, the Company does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.
Contact Information
Andrew Sims, CFO
Plus Therapeutics, Inc.
737-255-7194
ir@plustherapeutics.com
FAQ
Why did Plus Therapeutics (PSTV) receive a Nasdaq deficiency notice in May 2025?
Will PSTV be immediately delisted from Nasdaq due to the deficiency notice?
What is the deadline for Plus Therapeutics to submit its compliance plan to Nasdaq?
How long does Plus Therapeutics have to regain compliance with Nasdaq listing rules?
What must Plus Therapeutics do to regain Nasdaq compliance in 2025?
